Clinical Trial

A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single center, phase 1, randomized, double-blind, placebo-controlled sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of ISM8969 in healthy adults and elderly participants and obese adult participants at risk of cardiovascular disease.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-23
Trial Details
NCT Number NCT07581431
Lead Sponsor InSilico Medicine Hong Kong Limited
Conditions Healthy Subjects (HS), Obese Adult Participants at Risk of Cardiovascular Disease
Enrollment 100 participants
Start Date 2026-06-15
Primary Completion 2027-01-29 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-22